Mitoxantrone (DB01204): A Comprehensive Monograph on its Pharmacology, Clinical Utility, and Safety Profile

Executive Summary

Mitoxantrone is a synthetic small molecule belonging to the anthracenedione class of antineoplastic agents, structurally related to the anthracyclines.[1] It possesses a dual pharmacological identity, functioning as both a potent cytotoxic drug for cancer therapy and a significant immunomodulatory agent for treating autoimmune disease.[3] Its primary mechanism of action involves the inhibition of DNA topoisomerase II and intercalation into DNA, which disrupts DNA replication and repair, leading to cell death in both proliferating and non-proliferating cells.[1] Concurrently, it exerts profound immunosuppressive effects by inhibiting the proliferation and function of T-cells, B-cells, and macrophages, and by reducing the secretion of pro-inflammatory cytokines.[5]

This dual activity underpins its three main indications approved by the U.S. Food and Drug Administration (FDA): initial therapy for acute nonlymphocytic leukemia (ANLL) in combination with other agents; treatment of pain related to advanced hormone-refractory prostate cancer in combination with corticosteroids; and reduction of neurologic disability and relapse frequency in specific forms of multiple sclerosis (MS), namely secondary progressive, progressive relapsing, and worsening relapsing-remitting MS.[7]

Despite its clinical efficacy, the therapeutic use of mitoxantrone is severely constrained by a significant safety profile, which prompted the FDA to issue a black box warning.[10] The most critical risks include dose-dependent and potentially irreversible cardiotoxicity, which can manifest as congestive heart failure months to years after treatment cessation; severe, dose-limiting myelosuppression leading to life-threatening infections and bleeding; and the risk of developing therapy-related secondary malignancies, most notably acute myeloid leukemia.[11] Consequently, mitoxantrone therapy requires meticulous patient selection, strict adherence to a cumulative lifetime dose limit, and intensive hematologic and cardiac monitoring under the supervision of experienced physicians. Its clinical role has evolved, often being reserved for salvage therapy or specific high-risk patient populations as newer, safer alternatives have become available.[4]

Drug Identity, History, and Synthesis

Chemical and Physical Properties

Mitoxantrone is classified as a small molecule, synthetic anthracenedione-derived antineoplastic agent.[1] Chemically, it is a dihydroxyanthraquinone, specifically 1,4-dihydroxy-9,10-anthraquinone substituted at the 5 and 8 positions with 6-hydroxy-1,4-diazahexyl side chains.[1] This structure is central to its biological activity. The drug is typically formulated and administered as its hydrochloride salt for improved solubility and stability.[16]

The fundamental physicochemical and identification properties of mitoxantrone are summarized in Table 2.1. These identifiers are essential for accurate database cross-referencing, computational modeling, and regulatory documentation. The compound's negative LogP value of -3.1 indicates its hydrophilic nature, consistent with its formulation as an aqueous solution for intravenous administration.[1]

Table 2.1: Physicochemical and Identification Properties of Mitoxantrone

Property	Value	Source(s)
DrugBank ID	DB01204	1
Type	Small Molecule	1
IUPAC Name	1,4-dihydroxy-5,8-bis[2-(2-hydroxyethylamino)ethylamino]anthracene-9,10-dione	1
Molecular Formula	C22​H28​N4​O6​	1
Molecular Weight	444.48 g/mol (free base)	2
CAS Number	65271-80-9 (free base)	1
	70476-82-3 (hydrochloride salt)	1
PubChem CID	4212	1
ChEBI ID	CHEBI:50729	1
InChI	InChI=1S/C22H28N4O6/c27-11-9-23-5-7-25-13-1-2-14(26-8-6-24-10-12-28)18-17(13)21(31)19-15(29)3-4-16(30)20(19)22(18)32/h1-4,23-30H,5-12H2	1
InChIKey	KKZJGLLVHKMTCM-UHFFFAOYSA-N	1
SMILES	C1=CC(=C2C(=C1NCCNCCO)C(=O)C3=C(C=CC(=C3C2=O)O)O)NCCNCCO	1
Physical State	Solid; Light orange to Dark red to Black powder/crystal	20
Solubility (Water)	0.734 g/L	1
LogP	-3.1	1

Discovery and Development

The development of mitoxantrone is a classic example of a rational drug design program aimed at creating a "me-better" therapeutic agent. The work was initiated in the 1970s at the Medical Research Division of the American Cyanamid Company.[22] The primary impetus for this program was the significant clinical success of the anthracycline antibiotics, such as doxorubicin, which was tempered by their severe and often dose-limiting cardiotoxicity.[3] The scientific goal was to synthesize a new compound that retained the potent antineoplastic activity of the anthracycline pharmacophore—the planar, DNA-intercalating ring system—while mitigating its deleterious effects on cardiac tissue.[3]

The program began by investigating analogues of anthracenedione dyes, which were originally developed for the textile industry and were known to intercalate with DNA.[16] The initial lead compounds were identified as having immunomodulatory properties before their significant antitumor activity against transplantable murine tumors was discovered.[22] Following the synthesis and screening of a large series of analogues, mitoxantrone was selected for clinical development based on its superior potency and broad-spectrum preclinical efficacy.[22]

This development pathway illustrates a critical challenge in oncology drug design: the difficulty of separating therapeutic efficacy from toxicity when the mechanism of action targets a fundamental cellular process like DNA replication. While mitoxantrone was successfully designed to be less cardiotoxic than doxorubicin on a dose-by-dose basis, subsequent clinical experience and long-term surveillance revealed that it possesses its own profile of severe, dose-dependent toxicities, including a distinct form of cardiotoxicity and a risk of secondary leukemia.[11] This demonstrates that the effort to improve upon the anthracycline safety profile was only partially successful, ultimately trading one set of severe liabilities for another.

Clinical trials in the United States began in 1979, with the drug entering broader clinical use for cancer treatment in the mid-1980s.[16]

Chemical Synthesis

The synthesis of mitoxantrone, typically prepared as its hydrochloride salt for pharmaceutical use, is a multi-step process.[16] One common and well-documented pathway involves the reaction of leuco-1,4,5,8-tetrahydroxyanthraquinone with two equivalents of the side-chain precursor, 2-[(2-aminoethyl)amino]ethanol.[16] This condensation step attaches the characteristic basic side chains to the anthraquinone core.

The resulting intermediate, 1,4-dihydroxy-6,7-dihydro-5,8-bis[{2-[(2-hydroxyethyl)amino]ethyl}amino]-9,10-anthracenedione, is then subjected to an oxidation step to restore the aromaticity of the central ring system.[16] This aromatization can be achieved using an oxidant such as chloranil or by aeration with dry air.[16] Finally, the mitoxantrone free base is converted to its more stable and soluble dihydrochloride salt by treatment with hydrogen chloride, often in an ethanolic solution.[16] Alternative synthetic routes starting from chrysazin have also been described.[28] The overall process is reported to proceed under relatively mild and non-toxic conditions, which can be advantageous for large-scale manufacturing.[27] Quality control of the final product involves methods like liquid chromatography to assay for purity and identify potential impurities.[16]

Pharmacology and Mechanism of Action

The clinical utility of mitoxantrone in two disparate fields—oncology and neurology—is a direct consequence of its multifaceted pharmacology, which combines potent cytotoxic activity with broad immunosuppression. Its molecular actions target fundamental cellular processes related to DNA integrity and immune function.

Primary Antineoplastic Mechanism: Topoisomerase II Inhibition and DNA Interaction

The principal mechanism underlying mitoxantrone's anticancer effect is its function as a potent inhibitor of DNA topoisomerase II.[1] Topoisomerase II is a critical nuclear enzyme responsible for managing DNA topology by creating transient double-strand breaks to allow for the passage of another DNA strand, thereby resolving knots and tangles that arise during replication, transcription, and chromosome segregation.[5]

Mitoxantrone does not inhibit the enzyme directly but acts as a "topoisomerase II poison." It stabilizes the cleavable complex, which is the transient covalent intermediate formed between the enzyme and the DNA strand.[3] By trapping the enzyme in this state, mitoxantrone prevents the re-ligation of the DNA double-strand break. The collision of a replication fork with this stabilized complex converts the transient break into a permanent, lethal DNA lesion. The accumulation of these double-strand breaks triggers downstream cellular responses, including cell cycle arrest and apoptosis, ultimately leading to cell death.[3]

This topoisomerase poisoning is complemented by mitoxantrone's ability to directly interact with DNA. The planar, polycyclic anthracenedione core of the molecule physically inserts itself, or intercalates, between the base pairs of the DNA double helix.[2] This interaction is stabilized by hydrogen bonding and causes a physical distortion of the DNA structure, which interferes with the processes of DNA synthesis (replication) and DNA-dependent RNA synthesis (transcription).[2] This direct interference with DNA function contributes to its cytotoxic effects and can lead to chromosomal aberrations.[22]

A subtle but important distinction in its mechanism has been noted. While intercalation is a key feature, some studies suggest that in intact cells, mitoxantrone's binding to DNA may also be mediated by non-intercalative, electrostatic interactions between its positively charged side chains and the negatively charged phosphate backbone of DNA.[30] This different mode of interaction could account for the observed lack of complete clinical cross-resistance between mitoxantrone and classic anthracyclines like doxorubicin, suggesting a more complex and nuanced interaction with cellular DNA than simple intercalation alone.[30]

A key feature of its cytotoxic profile is its lack of cell-cycle phase specificity. Mitoxantrone has a cytocidal effect on both proliferating and non-proliferating cultured human cells, which distinguishes it from many antimetabolites and other cytotoxic agents that are only effective against actively dividing cells.[5]

Immunomodulatory Mechanisms

The efficacy of mitoxantrone in multiple sclerosis is not primarily due to its cytotoxicity but rather to its potent and broad-ranging immunosuppressive actions.[3] It targets multiple components of both the innate and adaptive immune systems.

• Inhibition of Immune Cell Proliferation: Mitoxantrone has been shown in vitro to inhibit the proliferation of key immune cell populations, including B lymphocytes, T lymphocytes, and macrophages.[5] This antiproliferative effect reduces the overall number of pathogenic immune cells that drive the autoimmune process in MS.
• Impairment of Antigen Presentation: The drug impairs the ability of antigen-presenting cells (APCs), such as macrophages and dendritic cells, to present antigens to T-cells.[5] This is a critical step in the activation of an adaptive immune response, and its disruption helps to quell the autoimmune attack.
• Modulation of Cytokine Secretion: Mitoxantrone significantly alters the cytokine milieu, shifting it away from a pro-inflammatory state. It decreases the secretion of key pro-inflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and interleukin-2 (IL-2), all of which are implicated in the pathology of MS.[5]
• Modulation of Lymphocyte Function: Beyond just inhibiting proliferation, mitoxantrone directly modulates immune cell function. It has been shown to enhance the activity of T-suppressor cells, which play a role in downregulating immune responses, while simultaneously inhibiting B-cell function and the production of antibodies.[6]
• Inhibition of Myelin Degradation: Directly relevant to the pathology of MS, mitoxantrone has been observed to inhibit macrophage-mediated degradation of myelin, the protective sheath around nerve fibers that is the primary target of the autoimmune attack in MS.[6]

Other Pharmacodynamic Effects

In addition to its primary mechanisms, mitoxantrone exhibits other biological activities that may contribute to its overall effect profile.

• Protein Kinase C (PKC) Inhibition: Mitoxantrone is an inhibitor of protein kinase C, with a reported half-maximal inhibitory concentration (IC50​) of 8.5 μM.[17] Kinetic analyses have shown that this inhibition is competitive with respect to the protein substrate (histone H1) and non-competitive with respect to ATP, indicating a specific interaction with the enzyme rather than a non-specific effect.[17]
• Apoptosis Induction: The culmination of mitoxantrone's cytotoxic and immunomodulatory effects is the induction of apoptosis, or programmed cell death. This has been demonstrated in various cell types, including B-chronic lymphocytic leukemia (B-CLL) cells.[3]
• Broad-Spectrum Activity: Preclinical studies have revealed that mitoxantrone possesses a wide range of biological activities beyond its use in cancer and MS. These include antiviral properties (e.g., activity against orthopoxviruses like cowpox and monkeypox, and inhibition of HIV-1 integrase), as well as antibacterial and antiprotozoal effects.[17]

Pharmacokinetics: ADME Profile

The pharmacokinetic (PK) profile of mitoxantrone is characterized by poor oral bioavailability, extensive tissue distribution, a very long terminal half-life, and hepatic metabolism. These properties are fundamental to understanding its dosing schedule, cumulative toxicity, and the need for specific clinical precautions.

Absorption and Distribution

• Absorption: When administered orally, mitoxantrone exhibits poor absorption, which necessitates its formulation for intravenous administration to achieve therapeutic concentrations.[3]
• Distribution: Following intravenous infusion, mitoxantrone distributes extensively into body tissues. This is reflected in its exceptionally large steady-state volume of distribution, which exceeds 1,000 L/m².[3] This extensive distribution means that during the elimination phase, tissue concentrations of the drug can be higher than those in the plasma.[5] It is known to distribute into the liver, thyroid, kidney, heart, and red blood cells.[3] While its distribution into the central nervous system (CNS) is generally low, it is sufficient to cross the blood-brain barrier and exert its immunomodulatory effects in patients with MS.[5]
• Protein Binding: Mitoxantrone is highly bound to plasma proteins, with reported binding percentages ranging from 78% to over 95%, primarily to albumin.[3] This binding is independent of drug concentration within the therapeutic range and is not significantly affected by the co-administration of other common drugs such as phenytoin, prednisone, or methotrexate.[5]

Metabolism

The liver is the primary site of mitoxantrone metabolism.[3] The specific metabolic pathways have not been fully elucidated, but it is known to be converted into inactive monocarboxylate and dicarboxylate metabolites.[3] In vitro studies suggest that mitoxantrone may be a weak inducer of the cytochrome P450 enzyme CYP2E1, though the clinical significance of this finding is inconclusive.[4]

Excretion and Half-Life

• Excretion: The primary route of elimination for mitoxantrone and its metabolites is via the feces (biliary excretion), which accounts for approximately 25% of the administered dose.[3] A smaller fraction, around 6-11%, is excreted in the urine.[3] A substantial portion of the drug (approximately 65%) is excreted unchanged in both feces and urine, indicating that metabolism is not the sole clearance mechanism.[3] The low reliance on renal excretion suggests that dose adjustments are unlikely to be necessary in patients with renal impairment, whereas the significant hepatic metabolism and biliary excretion mean that severe hepatic dysfunction can dramatically decrease clearance, necessitating caution and potential dose reduction.[30]
• Half-Life: The elimination of mitoxantrone from the plasma follows a tri-phasic pattern. There is a rapid initial distribution half-life (alpha phase) of 6 to 12 minutes, followed by an intermediate half-life (beta phase) of 1.1 to 3.1 hours.[5] Most significantly, it has a very long terminal elimination half-life (gamma phase) that ranges widely from 23 to 215 hours, with a median of approximately 75 hours (over 3 days).[3]

The pharmacokinetic characteristics of mitoxantrone, particularly its extensive tissue distribution and extremely long terminal half-life, are the direct pharmacological basis for critical aspects of its clinical use and risk management. The drug's slow elimination from deep tissue compartments means that it accumulates in the body with repeated administration. This accumulation is the reason its most severe toxicities, such as cardiotoxicity, are linked to the cumulative lifetime dose rather than the size of any single dose.[4] This fundamental PK-toxicity relationship mandates the use of intermittent dosing schedules (e.g., every 3 weeks or every 3 months) and the establishment of a strict cumulative lifetime dose limit to prevent irreversible organ damage.

Table 3.4: Summary of Key Pharmacokinetic Parameters for Mitoxantrone

Parameter	Value	Source(s)
Route of Administration	Intravenous	3
Oral Bioavailability	Poor	3
Plasma Protein Binding	78% to >95% (primarily albumin)	3
Volume of Distribution (Vdss​)	>1,000 L/m²	5
Metabolism	Hepatic (to inactive metabolites)	3
Primary Excretion Route	Feces (~25%)	3
Secondary Excretion Route	Urine (6-11%)	3
Terminal Half-Life (t1/2γ​)	23 - 215 hours (median ~75 hours)	3
Clearance	10.9 - 37.4 L/hr/m²	3

Clinical Efficacy and Therapeutic Applications

The clinical application of mitoxantrone is defined by its potency in diseases characterized by uncontrolled cell proliferation or aberrant immune responses. Its use is concentrated in specific hematologic malignancies, advanced prostate cancer, and aggressive forms of multiple sclerosis. However, its significant toxicity profile has led to an evolution in its therapeutic positioning, often shifting it from a frontline option to a salvage or niche therapy as safer alternatives have emerged.

FDA-Approved Indication: Acute Nonlymphocytic Leukemia (ANLL)

Mitoxantrone received its first FDA approval in 1987 for the initial therapy of ANLL in adults, a category that includes acute myelogenous leukemia (AML) and its subtypes (promyelocytic, monocytic, and erythroid leukemias).[7] It is approved for use in combination with other cytotoxic agents, most commonly cytarabine.[9]

Clinical trials have established its role in intensive induction and consolidation regimens. A phase II study in AML patients under the age of 60 demonstrated that a high-dose regimen of mitoxantrone (80 mg/m²) combined with high-dose cytarabine and etoposide could achieve a complete remission (CR) rate of 80% with acceptable toxicity.[34] Further randomized studies in older adults, while not reaching statistical significance, consistently favored high-dose mitoxantrone over standard doses in terms of CR rates and survival.[34]

Completed phase 3 trials have evaluated mitoxantrone as part of various combination chemotherapy backbones for AML, alongside drugs like cytarabine, daunorubicin, etoposide, and fludarabine (e.g., NCT01382147, NCT00880243, NCT00136084).[35] Its development continues, with active NCI-supported clinical trials exploring its integration with newer targeted therapies, such as the FLT3 inhibitor gilteritinib and the BCL-2 inhibitor venetoclax, for newly diagnosed or relapsed/refractory AML.[36] This reflects its enduring role as a potent cytotoxic component in the treatment of this aggressive malignancy.

FDA-Approved Indication: Hormone-Refractory Prostate Cancer

In 1996, mitoxantrone gained FDA approval for a second oncology indication: the treatment of pain associated with advanced hormone-refractory prostate cancer (now more commonly known as metastatic castration-resistant prostate cancer, mCRPC).[32] It is approved for use as an initial chemotherapy in combination with corticosteroids, typically prednisone.[4]

The combination of mitoxantrone and prednisone was once a standard first-line treatment for mCRPC, valued for its palliative effects on cancer-related pain. However, the therapeutic landscape for this disease has changed significantly. Subsequent clinical trials demonstrated that a combination of docetaxel and prednisone provided a survival advantage over mitoxantrone and prednisone, establishing the docetaxel-based regimen as the new standard of care.[4] As a result, mitoxantrone's role has shifted to that of a second-line or later option for patients who have progressed on or are ineligible for taxane-based chemotherapy.

Evidence supporting its use comes from several completed phase 3 trials, including S9916 (NCT00004001), which compared it to a docetaxel-based regimen, and S9921 (NCT00004124), which evaluated its use with prednisone.[37] An attempt to study its utility in an earlier, adjuvant setting for high-risk patients after radical prostatectomy (NCT00003858) was withdrawn before activation, indicating that its development was not pursued for earlier stages of the disease.[21]

FDA-Approved Indication: Multiple Sclerosis (MS)

In October 2000, mitoxantrone became one of the first cytotoxic agents to be approved by the FDA for the treatment of multiple sclerosis, marking a significant expansion of its use beyond oncology.[39] It is specifically indicated for reducing the frequency of clinical relapses and/or slowing the progression of neurologic disability in patients with secondary progressive MS (SPMS), progressive relapsing MS (PRMS), and worsening relapsing-remitting MS (RRMS).[4] It is explicitly not indicated for patients with primary progressive MS (PPMS).[8]

The approval was based on clinical trials, such as the MIMS (Mitoxantrone in Multiple Sclerosis) trial, which demonstrated its efficacy in reducing disease activity as measured by clinical relapses and MRI lesions.[40] However, due to its substantial and serious toxicity profile, particularly the risks of cardiotoxicity and secondary leukemia, its use in MS has always been carefully managed. It is generally reserved as a rescue or induction therapy for patients with highly active or rapidly worsening disease who have not responded to or are not candidates for other disease-modifying therapies (DMTs).[15]

The position of mitoxantrone in the MS treatment algorithm continues to evolve. Its use has declined significantly in recent years following the introduction of a new generation of highly effective and safer DMTs, such as natalizumab, fingolimod, and alemtuzumab.[15] These agents offer a more favorable risk-benefit profile for the long-term management of MS. Nevertheless, research into improving mitoxantrone's therapeutic index continues. A recent phase II clinical trial (NCT05496894) was initiated to evaluate a novel liposomal formulation of mitoxantrone for relapsing MS, aiming to alter its biodistribution to reduce systemic toxicity while preserving efficacy.[41] The status of this trial appears uncertain, with different sources reporting it as active, completed, or withdrawn, but it highlights ongoing efforts to potentially reclaim a role for this potent agent through modern drug delivery technology.[41]

Off-Label and Investigational Uses in Oncology

Beyond its approved indications, mitoxantrone is utilized off-label in several other oncologic settings, typically as part of salvage chemotherapy regimens for relapsed or refractory diseases.

• Lymphomas: Mitoxantrone is a component of the MINE combination chemotherapy regimen (mesna, ifosfamide, mitoxantrone, and etoposide). MINE is used as a second-line or subsequent therapy for various relapsed/refractory lymphomas, including classical Hodgkin lymphoma and several types of B-cell non-Hodgkin lymphoma such as follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), and AIDS-related lymphomas.[8] It is also used in the FMC regimen (fludarabine, mitoxantrone, cyclophosphamide) for symptomatic T-cell prolymphocytic leukemia.[8]
• Acute Lymphoblastic Leukemia (ALL): Mitoxantrone has a role in treating relapsed or refractory ALL. It has been shown to improve survival rates in children with relapsed ALL.[4] In adults, it is used in combination regimens such as FLAM (fludarabine, cytarabine, and mitoxantrone) for Ph-negative relapsed/refractory disease or Ph-positive disease that is refractory to tyrosine kinase inhibitors.[8]
• Other Solid Tumors: While mitoxantrone has been investigated and has Drugdex recommendations for use in anthracycline-resistant breast cancer, liver cancer, and ovarian cancer, it is important to note that these uses are generally not supported by current National Comprehensive Cancer Network (NCCN) guidelines.[8] In fact, the NCCN lists its use in invasive breast cancer as no longer recommended, further illustrating its evolving and often diminishing role in the face of newer therapies.[8]

Table 4.0: Summary of Key Clinical Trials for Mitoxantrone by Indication

Trial ID (NCT)	Phase	Indication	Intervention(s) / Comparator	Status
NCT00004124 (S9921)	3	Prostate Cancer	Mitoxantrone + Prednisone vs. Bicalutamide + Goserelin	Completed
NCT00004001 (S9916)	3	Prostate Cancer	Mitoxantrone + Prednisone vs. Docetaxel + Estramustine	Completed
NCT01382147	3	Acute Myeloid Leukemia	Mitoxantrone + Cytarabine vs. Daunorubicin + Cytarabine	Completed
MIMS Trial	N/A	Progressive Multiple Sclerosis	Mitoxantrone vs. Placebo	Completed
NCT05496894	2	Relapsing Multiple Sclerosis	Mitoxantrone Hydrochloride Liposome Injection (dose-ranging)	Withdrawn/Completed

Safety, Tolerability, and Risk Management

The clinical application of mitoxantrone is fundamentally governed by its severe and potentially life-threatening toxicity profile. The risks are so significant that they necessitated the issuance of an FDA black box warning in 2005, a pivotal event that reshaped its clinical use and underscored the importance of rigorous risk management protocols.[11] The history of mitoxantrone serves as a powerful case study in pharmacovigilance, as its most insidious long-term risks—delayed cardiotoxicity and therapy-related leukemia—were not fully appreciated until years of post-marketing data had accumulated. This demonstrates that the risk-benefit assessment for a potent cytotoxic drug is not static at the time of approval but is a dynamic process that evolves over the entire lifecycle of the product.

FDA Black Box Warnings: A Detailed Analysis

The black box warning for mitoxantrone highlights three principal areas of concern: cardiotoxicity, myelosuppression, and the risk of secondary malignancies. Administration should only be performed under the supervision of a physician experienced in cytotoxic chemotherapy.[13]

Cardiotoxicity

The most notorious toxicity associated with mitoxantrone is its potential to cause cardiac damage, which can be irreversible and fatal.[10] This toxicity can manifest as a reduction in left ventricular ejection fraction (LVEF) or as overt congestive heart failure (CHF).[11] A particularly dangerous feature of this toxicity is its potential for delayed onset, with cardiac events occurring months or even years after the completion of therapy, necessitating long-term patient surveillance.[11]

The risk of cardiotoxicity is clearly dose-dependent and is directly related to the total cumulative lifetime dose of mitoxantrone a patient receives.[4] To mitigate this risk, a maximum cumulative lifetime dose of 140 mg/m² is strongly recommended, particularly for patients with MS.[9] Post-marketing reports have indicated that cardiotoxicity can occur even at cumulative doses below 100 mg/m².[11] Risk factors that can exacerbate this toxicity include pre-existing cardiovascular disease, prior radiation therapy to the mediastinal area, and previous treatment with other cardiotoxic agents, especially anthracyclines.[3] The incidence of systolic dysfunction in MS patients treated with mitoxantrone is estimated to be approximately 12%, with a number needed to harm of 8.[14]

Myelosuppression

Bone marrow suppression, or myelosuppression, is the primary acute dose-limiting toxicity of mitoxantrone.[3] It manifests as leukopenia (a decrease in white blood cells), neutropenia (a decrease in neutrophils), and thrombocytopenia (a decrease in platelets).[3] This suppression can be severe and can lead to life-threatening complications, including serious infections due to neutropenia and significant bleeding events due to thrombocytopenia.[12]

The nadir, or lowest point of blood cell counts, typically occurs around day 10 after administration, with recovery usually by day 21.[3] Due to this profound effect on the bone marrow, mitoxantrone is generally contraindicated for use in patients (except those with ANLL) who have a baseline absolute neutrophil count of less than 1,500 cells/mm³.[12]

Secondary Malignancies

A grave long-term risk of mitoxantrone therapy is the development of secondary cancers, specifically therapy-related acute leukemia (TRAL).[11] The most commonly reported types are acute myelogenous leukemia (AML) and acute promyelocytic leukemia (APL).[3] This risk is significant enough that the International Agency for Research on Cancer (IARC) has classified mitoxantrone as a Group 2B agent, meaning it is "possibly carcinogenic to humans".[16]

The risk of TRAL is higher in patients receiving high doses of mitoxantrone or when it is used in combination with other DNA-damaging chemotherapeutic agents or radiation therapy.[3] Post-marketing surveillance data from MS patient populations suggest that the risk is higher than was initially estimated from pre-market trials, with an approximate incidence of 0.8% and a number needed to harm of 123.[11]

Common and Other Serious Adverse Events

In addition to the black-boxed warnings, mitoxantrone is associated with a wide range of other adverse effects.

• Common Adverse Events: The most frequently reported side effects include gastrointestinal issues such as nausea and vomiting, alopecia (hair loss, which is usually temporary), and menstrual disorders, including amenorrhea, which can sometimes be permanent.[4] Due to its myelosuppressive effects, infections of the upper respiratory and urinary tracts are also common.[3] Other common effects include diarrhea, constipation, stomatitis or mucositis (sores in the mouth), and profound fatigue.[3]
• Other Serious Adverse Events: Beyond the black box warnings, other serious risks include hepatotoxicity, evidenced by elevations in liver enzymes; effects on fertility, including irreversible ovarian failure in women and reduced spermatogenesis in men; and hypersensitivity reactions, which can range from hives and rash to, in rare cases, life-threatening anaphylaxis.[3]
• Unique Side Effects: A notable and generally benign side effect of mitoxantrone is its dark blue color, which can cause a temporary blue-green discoloration of the urine for about 24 hours after infusion and a bluish tint to the sclera (the whites of the eyes) for a few days. Patients should be counseled about this effect to avoid undue alarm.[13]

Table 5.2: Frequency of Adverse Events Associated with Mitoxantrone Therapy

System Organ Class	Adverse Event	Reported Incidence	Source(s)
Hematologic	Leukopenia / Neutropenia	9-100% (Dose-limiting)	3
	Thrombocytopenia	33-39%	3
Cardiovascular	Decreased LVEF / CHF	~12% (systolic dysfunction)	14
	Arrhythmia	3-18%	3
Infections	Upper Respiratory Tract Infection	7-53%	3
	Urinary Tract Infection	7-32%	3
Gastrointestinal	Nausea / Vomiting	Up to 55%	3
	Diarrhea	Up to 25%	3
	Stomatitis / Mucositis	Up to 15%	3
Dermatologic	Alopecia (Hair Loss)	Up to 38%	12
Reproductive	Amenorrhea	Up to 28%	3
General	Weakness / Fatigue	24%	3

Contraindications and Precautions

• Contraindications: Mitoxantrone is contraindicated in patients with a known hypersensitivity to the drug or any of its components.[45] As previously noted, it is also contraindicated in non-leukemia patients with a baseline neutrophil count below 1,500 cells/mm³.[45]
• Precautions: Extreme caution is warranted in patients with pre-existing myelosuppression, as the drug will exacerbate this condition.[45] Patients with severe hepatic impairment require special consideration, as their reduced ability to clear the drug leads to a threefold increase in exposure (AUC), likely necessitating dose reduction.[3] Any pre-existing systemic infections should be fully treated prior to initiating mitoxantrone therapy.[45]

Required Clinical Monitoring

The narrow therapeutic index and severe toxicity profile of mitoxantrone mandate a rigorous and comprehensive monitoring plan.

• Hematologic Monitoring: Frequent monitoring of peripheral blood cell counts (complete blood count with differential) is essential before each treatment cycle and as clinically indicated to assess the degree of myelosuppression and ensure adequate hematologic recovery between doses.[13]
• Cardiac Monitoring: This is a cornerstone of safe mitoxantrone use. A baseline evaluation of LVEF, using either an echocardiogram or a multigated acquisition (MUGA) scan, is mandatory before starting therapy.[4] For MS patients, LVEF must be re-evaluated before every dose. Treatment should be discontinued if a patient experiences a clinically significant reduction in LVEF or if their LVEF falls below the lower limit of normal.[45] Furthermore, because of the risk of delayed cardiotoxicity, annual cardiac function testing is recommended for up to five years after treatment has been completed.[11]
• Hepatic Monitoring: Liver function tests (e.g., bilirubin, SGOT) should be monitored periodically, especially in patients with known or suspected liver disease, as hepatic impairment significantly alters drug clearance.[3]
• Pregnancy Testing: For all women of childbearing potential, a pregnancy test must be performed and be negative before each dose of mitoxantrone is administered.[12]

Dosing, Administration, and Special Considerations

The management of mitoxantrone therapy is a highly specialized and protocol-driven process, a direct reflection of its narrow therapeutic index and potential for severe toxicity. Every aspect, from dose calculation and lifetime accumulation limits to the specifics of intravenous administration and population-based precautions, is meticulously defined to mitigate predictable and severe risks. This rigid framework underscores that mitoxantrone is a high-risk medication that leaves little room for error and should only be handled by experienced specialists in facilities equipped to manage its potential complications, as stipulated in its black box warning.[13]

Dosing Regimens by Indication

Dosing for mitoxantrone is calculated based on the patient's body surface area (mg/m2) and varies by indication.

• Acute Nonlymphocytic Leukemia (ANLL):
• Induction Therapy: 12 mg/m² administered as a daily intravenous infusion for 3 consecutive days (Days 1, 2, and 3), typically in combination with cytarabine.[9]
• Consolidation Therapy: Following induction and hematologic recovery, consolidation cycles consist of 12 mg/m² daily for 2 consecutive days, again in combination with cytarabine.[9]
• Hormone-Refractory Prostate Cancer: 12 to 14 mg/m² administered as a single intravenous infusion every 21 days, in combination with corticosteroids.[9]
• Multiple Sclerosis (MS): 12 mg/m² administered as a short intravenous infusion every 3 months.[9] For this indication, adherence to the cumulative lifetime dose limit is paramount. The total dose a patient receives over their lifetime should generally not exceed 140 mg/m² to minimize the risk of irreversible cardiotoxicity.[9]

When used in combination with other chemotherapy agents, the initial dose of mitoxantrone may need to be reduced by 2-4 mg/m² below the standard single-agent dose to account for overlapping toxicities.[3]

Preparation and Intravenous Administration

Proper handling and administration are critical to ensure patient safety and drug stability.

• Preparation: Mitoxantrone is supplied as a dark blue concentrate that MUST be diluted prior to administration. The dose should be diluted in at least 50 mL of a compatible solution, such as 0.9% Sodium Chloride Injection or 5% Dextrose Injection.[44]
• Administration: The diluted solution is given as an intravenous infusion, typically over a period of 5 to 15 minutes for MS or 15 to 30 minutes for oncology indications.[9] It must be administered into the tubing of a freely flowing intravenous solution to ensure rapid dilution and minimize the risk of extravasation (leakage of the drug into surrounding tissue), which can cause severe local tissue damage.[45]
• Incompatibilities: Mitoxantrone should NOT be mixed in the same infusion bag or line with heparin, as a precipitate may form.[44] Due to a lack of specific compatibility data, it is recommended not to mix it with other drugs in the same infusion.[44]
• Route Warning: Mitoxantrone is for intravenous use only. It must never be administered by subcutaneous, intramuscular, or intra-arterial routes. Intrathecal administration is absolutely contraindicated and has been associated with severe neurological injury, including paralysis and death.[45]

Use in Special Populations

The use of mitoxantrone requires special consideration and often contraindication in vulnerable populations.

• Pregnancy and Lactation: Mitoxantrone is classified as FDA Pregnancy Category D, indicating positive evidence of human fetal risk.[45] It is considered a potential human teratogen and can cause fetal harm.[13] Therefore, women of childbearing potential must avoid becoming pregnant during therapy. Effective contraception is mandatory for both female and male patients during treatment and for a recommended period of at least six months after treatment cessation.[13] Mitoxantrone is excreted in human breast milk in significant concentrations and can remain detectable for up to one month after the last dose. Due to the potential for serious adverse reactions in the nursing infant, breastfeeding is contraindicated during therapy.[1]
• Pediatric Use: The pharmacokinetics of mitoxantrone in the pediatric population are unknown.[5] While it is used off-label in combination regimens for pediatric acute lymphoblastic leukemia, its use requires special care and close monitoring by physicians experienced in pediatric oncology.[4]
• Geriatric Use: Pharmacokinetic studies have shown that systemic clearance of mitoxantrone may be decreased in elderly patients compared to younger adults.[5] This could lead to increased drug exposure and a higher risk of toxicity, warranting careful monitoring.
• Hepatic Impairment: Patients with severe hepatic dysfunction exhibit significantly reduced clearance of mitoxantrone, resulting in a threefold increase in the area under the curve (AUC).[3] This dramatically increases the risk of toxicity, and dose reduction is likely necessary, although specific guidelines have not been established.[30]
• Renal Impairment: The pharmacokinetics in patients with renal impairment are unknown.[5] However, given that renal excretion accounts for a small percentage of total drug elimination, it is considered unlikely that dose adjustments are required for patients with compromised renal function.[30]

Significant Drug-Drug Interactions

Mitoxantrone has several clinically significant drug-drug interactions that can increase toxicity or reduce efficacy.

• Immunosuppressive Agents and Vaccines: Co-administration with other immunosuppressive or myelosuppressive therapies results in additive effects, increasing the risk of severe immunosuppression and infection.[45] Live or live-attenuated vaccines are contraindicated during and for at least 3 months after mitoxantrone therapy, as they can cause disseminated infections in an immunocompromised host and the immune response to the vaccine may be diminished.[45]
• BCRP Substrate Interactions: Mitoxantrone is a substrate of the Breast Cancer Resistance Protein (BCRP), an efflux transporter. Co-administration with potent BCRP inhibitors (e.g., darolutamide, enasidenib, leniolisib) can significantly increase plasma concentrations of mitoxantrone, thereby increasing the risk of toxicity. This combination should be avoided or, if unavoidable, used with extreme caution and consideration of a mitoxantrone dose reduction.[45]
• Cardiotoxic Agents: The risk of cardiotoxicity is additive when mitoxantrone is used with other agents known to affect cardiac function, such as other anthracyclines or trastuzumab.[46]
• Drugs Associated with Neutropenia: Concomitant use with other drugs known to cause neutropenia or agranulocytosis (e.g., deferiprone) should be avoided due to the potential for pharmacodynamic synergism and profound neutropenia.[45]

Commercial Information and Conclusion

Commercial and Regulatory Information

• Brand Names: In the United States, mitoxantrone was marketed under the brand name Novantrone®.[4] While the brand name product has been discontinued in the U.S., generic versions of mitoxantrone for injection are available.[44] Internationally, mitoxantrone is marketed under a wide variety of brand names, including Mitroxone, Neotalem, Onkotrone, and Pralifan, among many others across different countries.[17]
• FDA Approval History: The regulatory journey of mitoxantrone in the U.S. includes three key approvals for distinct indications:
• December 1987: Initial FDA approval for use in combination therapy for adult acute nonlymphocytic leukemia (ANLL).[32]
• 1996: Approval for use in combination with corticosteroids for the treatment of pain related to advanced hormone-refractory prostate cancer.[32]
• October 2000: Approval for reducing neurologic disability and/or relapse frequency in specific forms of multiple sclerosis.[39]
• Regulatory Classification: Reflecting the long-term risk of secondary malignancies, the International Agency for Research on Cancer (IARC) has evaluated mitoxantrone and classified it as a Group 2B agent, signifying that it is "possibly carcinogenic to humans".[16]

Conclusion and Future Perspectives

Mitoxantrone stands as a potent therapeutic agent born from a rational drug design effort to improve upon the safety profile of anthracyclines. This endeavor was only partially successful, creating a drug with a distinct but equally challenging set of severe toxicities. Its clinical legacy is defined by a fundamental tension between its proven efficacy in aggressive diseases and the life-limiting risks of irreversible cardiotoxicity, profound myelosuppression, and secondary leukemia.

The dual mechanism of action—combining DNA topoisomerase II poisoning with broad immunosuppression—is the cornerstone of its unique therapeutic footprint, granting it utility in both oncology and autoimmune neurology. However, this same broad mechanism is the source of its significant off-target effects. The clinical role of mitoxantrone has been in a state of continuous evolution. In both prostate cancer and multiple sclerosis, it has transitioned from a frontline therapy to a later-line or salvage option, largely displaced by the development of newer agents with superior efficacy or, more often, a more favorable safety profile.[4] This trend highlights a broader shift in medicine away from broadly cytotoxic agents and toward more targeted and less toxic therapies.

The future of mitoxantrone, or agents derived from it, likely lies in strategies designed to fundamentally improve its therapeutic index. The most promising avenue for this is through advanced drug delivery systems. The investigation into a liposomal formulation of mitoxantrone (as seen in trial NCT05496894) represents a key step in this direction.[41] By encapsulating the drug, such formulations aim to alter its pharmacokinetic properties and biodistribution, potentially concentrating its effects at the site of disease while sparing sensitive tissues like the heart. If successful, this approach could mitigate systemic toxicity and perhaps reclaim a safer, more defined role for this powerful molecule in the modern therapeutic arsenal. Mitoxantrone thus serves as both a valuable clinical tool for specific high-risk scenarios and a salient lesson in the enduring challenge of separating efficacy from toxicity in drug development.

Works cited

1. Mitoxantrone | C22H28N4O6 | CID 4212 - PubChem, accessed July 21, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Mitoxantrone
2. Mitoxantrone | 65271-80-9 | FD26022 - Biosynth, accessed July 21, 2025, https://www.biosynth.com/p/FD26022/65271-80-9-mitoxantrone
3. DRUG NAME: Mitoxantrone - BC Cancer, accessed July 21, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Mitoxantrone_monograph.pdf
4. Mitoxantrone - Wikipedia, accessed July 21, 2025, https://en.wikipedia.org/wiki/Mitoxantrone
5. mitoxantrone injection, USP Clinical Pharmacology | Pfizer Medical ..., accessed July 21, 2025, https://www.pfizermedicalinformation.com/mitoxantrone/clinical-pharmacology
6. www.neurology.org, accessed July 21, 2025, https://www.neurology.org/doi/pdfdirect/10.1212/WNL.63.12_suppl_6.S15#:~:text=It%20impairs%20antigen%20presentation%20and,inhibits%20macrophage%2Dmediated%20myelin%20degradation.
7. Mitoxantrone (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 21, 2025, https://www.mayoclinic.org/drugs-supplements/mitoxantrone-intravenous-route/description/drg-20064849
8. Mitoxantrone Clinical Policy: Mitoxantrone, accessed July 21, 2025, https://www.ilyouthcare.com/content/dam/centene/illinois/pdfs/IL.PHAR.258_Mitoxantrone_Novantrone_HFS_PDL_4.18.23.pdf
9. Clinical Policy: Mitoxantrone (Novantrone) - PA Health & Wellness, accessed July 21, 2025, https://www.pahealthwellness.com/content/dam/centene/Pennsylvania/policies/pharmacy-policies/PA.CP.PHAR.258%20Mitoxantrone%20(Novantrone).pdf
10. www.medicalnewstoday.com, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/322211#:~:text=The%20Food%20and%20Drug%20Administration,a%20higher%20risk%20of%20infection
11. The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology[image] - PMC, accessed July 21, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2871006/
12. Mitoxantrone: Uses, side effects, and risks - Medical News Today, accessed July 21, 2025, https://www.medicalnewstoday.com/articles/322211
13. Mitoxantrone Injection: MedlinePlus Drug Information, accessed July 21, 2025, https://medlineplus.gov/druginfo/meds/a608019.html
14. The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis [RETIRED]: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/20439849/
15. Mitoxantrone (Novantrone) - MS Trust, accessed July 21, 2025, https://mstrust.org.uk/a-z/mitoxantrone-novantrone
16. MITOXANTRONE 1. Exposure Data - IARC Publications, accessed July 21, 2025, https://publications.iarc.fr/_publications/media/download/2514/5871a3360d3fc6a920ea908a22e17f80c0a2fba7.pdf
17. Mitoxantrone free base | CAS#65271-80-9 - MedKoo Biosciences, accessed July 21, 2025, https://www.medkoo.com/products/36995
18. 3D structure for Mitoxantrone (DB01204) | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/structures/small_molecule_drugs/DB01204
19. Mitoxantrone | CAS 65271-80-9 | SCBT - Santa Cruz Biotechnology, accessed July 21, 2025, https://www.scbt.com/p/mitoxantrone-65271-80-9
20. Mitoxantrone 65271-80-9 | TCI AMERICA, accessed July 21, 2025, https://www.tcichemicals.com/US/en/p/M3133
21. Mitoxantrone (Mitozantrone) | Top II/PKC Inhibitor - Ambeed.com, accessed July 21, 2025, https://www.ambeed.com/products/mitoxantrone.html
22. Development of mitoxantrone - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/2410393/
23. Mitoxantrone, More than Just Another Topoisomerase II Poison - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/26286294/
24. Definition of mitoxantrone hydrochloride - NCI Drug Dictionary, accessed July 21, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/mitoxantrone-hydrochloride
25. Mitoxantrone: A New Anticancer Drug with Significant Clinical ..., accessed July 21, 2025, https://www.acpjournals.org/doi/10.7326/0003-4819-105-1-67
26. Mitoxantrone: a new anticancer drug with significant clinical activity - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/3521429/
27. Synthesis and Quality Evaluation of Mitoxantrone | China Pharmacy;(12): 1769-1774, 2019., accessed July 21, 2025, https://pesquisa.bvsalud.org/gim/resource/pt/wpr-817229
28. Synthesis of Mitoxantrone Analogues and their in-vitro Cytotoxicity - International Journal of ChemTech Research, accessed July 21, 2025, https://sphinxsai.com/vol3.no2/chem/chempdf/CT=29(690-694)AJ11.pdf
29. Mechanism of action of mitoxantrone - Neurology.org, accessed July 21, 2025, https://www.neurology.org/doi/pdfdirect/10.1212/WNL.63.12_suppl_6.S15
30. Pharmacology of mitoxantrone: mode of action and pharmacokinetics - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/4040505/
31. Mitoxantrone in progressive multiple sclerosis: when and how to treat? - PubMed, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/12559512/
32. Novantrone, Mitoxantrone hydrochloride - accessdata.fda.gov, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21120.pdf_Novantrone_Pharmr_P1.pdf
33. Search Orphan Drug Designations and Approvals - FDA, accessed July 21, 2025, https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=19287
34. High-dose mitoxantrone in acute leukaemia: New York Medical College experience, accessed July 21, 2025, https://pubmed.ncbi.nlm.nih.gov/9460340/
35. Mitoxantrone Completed Phase 3 Trials for Acute Myeloid Leukemia Treatment - DrugBank, accessed July 21, 2025, https://go.drugbank.com/drugs/DB01204/clinical_trials?conditions=DBCOND0029883&phase=3&purpose=treatment&status=completed
36. Clinical Trials Using Mitoxantrone Hydrochloride - NCI, accessed July 21, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/mitoxantrone-hydrochloride
37. Mitoxantrone Completed Phase 3 Trials for Prostate Cancer Treatment | DrugBank Online, accessed July 21, 2025, https://go.drugbank.com/drugs/DB01204/clinical_trials?conditions=DBCOND0062462&phase=3&purpose=treatment&status=completed
38. Mitoxantrone Following Surgery in Treating Patients With Prostate Cancer at High Risk for Recurrence | ClinicalTrials.gov, accessed July 21, 2025, https://clinicaltrials.gov/ct2/show/NCT00003858
39. Drug Approval Package: Novantrone (mitoxantrone hydrochloride) NDA, accessed July 21, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21120_Novantrone.cfm
40. An open‐trial evaluation of mitoxantrone in the treatment of progressive MS - Neurology.org, accessed July 21, 2025, https://www.neurology.org/doi/10.1212/WNL.43.7.1401
41. A Study of Mitoxantrone Hydrochloride Liposome Injection for Relapsing Multiple Sclerosis, accessed July 21, 2025, https://clinicaltrials.gov/study/NCT05496894
42. 13 - DDrare: Database of Drug Development for Rare Diseases, accessed July 21, 2025, https://ddrare.nibn.go.jp/cgi-bin/disease_who_e.cgi?id=13&query=%22mitoxantrone%22
43. Clinical Trials on Idiopathic Inflammatory Demyelinating Disorders of, accessed July 21, 2025, https://ichgcp.net/amp/clinical-trials-registry/research/list?cond=Idiopathic%2BInflammatory%2BDemyelinating%2BDisorders%2Bof%2Bthe%2BCentral%2BNervous%2BSystem&page=39
44. Novantrone (Mitoxantrone for Injection Concentrate): Side Effects, Uses, Dosage, Interactions, Warnings - RxList, accessed July 21, 2025, https://www.rxlist.com/novantrone-drug.htm
45. (mitoxantrone) dosing, indications, interactions, adverse effects, and ..., accessed July 21, 2025, https://reference.medscape.com/drug/mitoxantrone-342186
46. Mitoxantrone (Novantrone): Uses & Side Effects - Cleveland Clinic, accessed July 21, 2025, https://my.clevelandclinic.org/health/drugs/20470-mitoxantrone-injection
47. my.clevelandclinic.org, accessed July 21, 2025, https://my.clevelandclinic.org/health/drugs/20470-mitoxantrone-injection#:~:text=Mitoxantrone%20is%20a%20chemotherapy%20medication,of%20mitoxantrone%20is%20Novantrone%C2%AE.
48. MitoXANTRONE | Drug Lookup | Pediatric Care Online - AAP Publications, accessed July 21, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5329/MitoXANTRONE